Blood protein signature for the early diagnosis of Alzheimer disease.
Alzheimer disease (AD) has become one of the main health concerns for the elderly population in the United States. Current treatments target symptoms only, but several advanced clinical trials are testing new drugs that are potentially disease modifying. Because AD is still difficult to diagnose in its earliest stages and the disease process is estimated to start many years before current clinical diagnosis is made, accurate and simple diagnostic tools are urgently needed. We recently described a blood-based panel of secreted signaling proteins that distinguishes between blinded samples from patients with AD and control subjects with high accuracy. The same proteins also predicted progression to AD in preclinical patients with mild cognitive impairment several years before clinical diagnosis for AD was made. Herein, we describe these findings and discuss the potential for a more general application of our proteomic approach in understanding and diagnosing disease.
Britschgi
Markus
M
Department of Neurology and Neurological Sciences, Stanford University School of Medicine, 300 Pasteur Dr, Stanford, CA 94305-5235, USA.
Wyss-Coray
Tony
T
D000544:Alzheimer Disease / Q000097:blood* / Q000175:diagnosis* / Q000503:physiopathology; D015415:Biomarkers / Q000032:analysis / Q000097:blood; D018925:Chemokines / Q000032:analysis / Q000097:blood*; D016207:Cytokines / Q000032:analysis / Q000097:blood*; D042241:Early Diagnosis; D004660:Encephalitis / Q000097:blood / Q000503:physiopathology; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000032:analysis / Q000097:blood*; D011237:Predictive Value of Tests; D015398:Signal Transduction / Q000502:physiology
D015415:Biomarkers; D018925:Chemokines; D016207:Cytokines; D036341:Intercellular Signaling Peptides and Proteins